Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02079636 · ClinicalTrials.gov registry record · Phase 1
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 142
- Enrollment target
NCT02079636 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 142 participants.
The verdict
NCT02079636, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 142 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.
Interventions
- DRUG Pemetrexed
- DRUG Abemaciclib
- DRUG Gemcitabine
- DRUG Ramucirumab
- DRUG LY3023414
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2014-03-28 |
| Est. Completion | 2019-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02079636
The ClinicalTrials.gov registry entry for NCT02079636 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pemetrexed is the first listed.
NCT02079636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02079636 about?
NCT02079636 is a clinical study titled "A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)". The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combinatio...
What is the current status of trial NCT02079636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 142 participants. The study started on 2014-03-28. Estimated completion is 2019-08-29.
What interventions are being tested in trial NCT02079636?
The interventions under investigation include: Pemetrexed (DRUG), Abemaciclib (DRUG), Gemcitabine (DRUG), Ramucirumab (DRUG), LY3023414 (DRUG).
Who is sponsoring clinical trial NCT02079636?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.